Literature DB >> 35928075

Vulval Intraepithelial Neoplasia 3: A Clinico-Pathological Review in a Tertiary Care Centre Over 10 Years.

Karthik C Bassetty1, Anitha Thomas1, Rachel G Chandy1, Dhanya S Thomas1, Vinotha Thomas1, Abraham Peedicayil1, Ajit Sebastian1.   

Abstract

Objectives: Vulval Intraepithelial Neoplasia 3 (VIN) is a chronic, premalignant condition affecting the vulval skin. The age standardised incidence is approximately one per 100,000 women, with a peak at 30-49 years of age, and has risen over recent decades. This study would analyse the pattern of presentation, diagnosis, treatment and follow up of patients diagnosed with VIN 3 over a period of ten years at a tertiary care centre in India. Materials and
Methods: This was a retrospective study conducted on all patients diagnosed to have VIN 3 between 1 January 2010 to 30 November 2019 in the Department of Gynaecologic Oncology, Christian Medical College, Vellore were included in this study. The outpatient records of the patients were obtained from an electronic registry.
Results: A total of 18 patients were diagnosed of VIN 3 during this time period. Sixteen patients were older than 50 years. Abnormal PAP was noted in 10 patients (HSIL-7, LSIL-2, ASC-H-1). Four patients had coexisting VAIN 3. About 16 patients underwent primary simple vulvectomy or wide local excision. Two patients were managed conservatively. Nine patients had recurrence with mean disease free interval of 12.5 months (4-36 months). Cryotherapy was used in 2 patients. Imiquimod was used in 3 patients. Surgical margins was achieved in 7 patients out of which 5 patients had recurrence. About 50% of patients with involved margins on biopsy had recurrence. Mean duration of follow up was 17 months (4-105 months). About 8 patients developed squamous cell carcinoma of genital tract on follow up.
Conclusion: VIN 3 has a high rate of progression to invasive SCC. Regression of VIN is rare. Proper follow up and treatment of VIN 3 goes a long way in preventing the morbidity associated with vulval cancer. © Federation of Obstetric & Gynecological Societies of India 2022.

Entities:  

Keywords:  Management; Recurrence; VIN3; Vulva

Year:  2022        PMID: 35928075      PMCID: PMC9343544          DOI: 10.1007/s13224-022-01659-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  23 in total

1.  Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee.

Authors:  Mario Sideri; Ronald W Jones; Edward J Wilkinson; Mario Preti; Debra S Heller; James Scurry; Hope Haefner; Sallie Neill
Journal:  J Reprod Med       Date:  2005-11       Impact factor: 0.142

2.  Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma.

Authors:  Hedwig P van de Nieuwenhof; Johan Bulten; Harrie Hollema; Rianne G Dommerholt; Leon F A G Massuger; Ate G J van der Zee; Joanne A de Hullu; Leon C L T van Kempen
Journal:  Mod Pathol       Date:  2010-11-05       Impact factor: 7.842

3.  Trends in the incidence of invasive and in situ vulvar carcinoma.

Authors:  Patricia L Judson; Elizabeth B Habermann; Nancy N Baxter; Sara B Durham; Beth A Virnig
Journal:  Obstet Gynecol       Date:  2006-05       Impact factor: 7.661

4.  Restricted surgical management of vulvar intraepithelial neoplasia 3: Focus on exclusion of invasion and on relief of symptoms.

Authors:  M. van Beurden; N. van Der Vange; F. J. W. ten Kate; A. J. M. de Craen; M. S. Schilthuis; F. B. Lammes
Journal:  Int J Gynecol Cancer       Date:  1998-01       Impact factor: 3.437

Review 5.  Vulval intraepithelial neoplasia: current perspectives.

Authors:  R W Jones
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

6.  The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges.

Authors:  Susan M Bigby; Lois J Eva; Kah Leng Fong; Ronald W Jones
Journal:  Int J Gynecol Pathol       Date:  2016-11       Impact factor: 2.762

7.  Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence.

Authors:  S C Modesitt; A B Waters; L Walton; W C Fowler; L Van Le
Journal:  Obstet Gynecol       Date:  1998-12       Impact factor: 7.661

8.  Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential.

Authors:  U Hørding; J Junge; H Poulsen; F Lundvall
Journal:  Gynecol Oncol       Date:  1995-02       Impact factor: 5.482

9.  Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.

Authors:  Amanda Tristram; Christopher N Hurt; Tracie Madden; Ned Powell; Stephen Man; Sam Hibbitts; Peter Dutton; Sadie Jones; Andrew J Nordin; Raj Naik; Alison Fiander; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2014-10-07       Impact factor: 41.316

Review 10.  VIN usual type-from the past to the future.

Authors:  Mario Preti; Sarah Igidbashian; Silvano Costa; Paolo Cristoforoni; Luciano Mariani; Massimo Origoni; Maria T Sandri; Sara Boveri; Noemi Spolti; Laura Spinaci; Francesca Sanvito; Eleonora P Preti; Adriana Falasca; Gianluigi Radici; Leonardo Micheletti
Journal:  Ecancermedicalscience       Date:  2015-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.